Cellebrite shareholders approve all 2025 AGM proposals

Cellebrate DI Ltd. reports that shareholders approved all proposals presented at its annual general meeting of shareholders held on September 19, 2025.

Accepted by SEC EDGAR 09/22/2025 - 08:21 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Cellebrate DI Ltd. reports that shareholders approved all proposals presented at its annual general meeting of shareholders held on September 19, 2025. These proposals were adopted by the requisite majority in accordance with Israeli law and the company’s articles, as outlined in the proxy statement previously provided to investors.

The meeting had strong participation, with 188,039,771 ordinary shares represented, equal to approximately 76.82% of issued and outstanding ordinary shares as of the record date. This report is also incorporated by reference into Cellebrite’s existing registration statements on Form S-8 and Form F-3.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cellebrite DI Ltd. (CLBT) announce in this Form 6-K?

Cellebrite DI Ltd. announced that shareholders approved all proposals presented at its annual general meeting of shareholders held on September 19, 2025, in accordance with Israeli Companies Law and the company’s articles of association.

Were all shareholder proposals approved at the Cellebrite (CLBT) 2025 annual meeting?

Yes. The company states that shareholders approved all of the proposals brought before the 2025 annual general meeting by the requisite majority described in the previously distributed proxy statement.

What was shareholder participation at Cellebrite’s September 19, 2025 meeting?

A total of 188,039,771 ordinary shares were present or represented by proxy at the meeting, representing approximately 76.82% of the issued and outstanding ordinary shares as of the record date.

How does this Form 6-K relate to Cellebrite’s prior proxy statement?

The approved proposals were described in the proxy statement that was attached as Exhibit 99.1 to a prior Form 6-K furnished on August 15, 2025 and sent to shareholders in connection with the annual meeting.

Which registration statements does this Cellebrite (CLBT) Form 6-K affect?

This Form 6-K is incorporated by reference into Cellebrite’s registration statements on Form S-8 (File Nos. 333-260878 and 333-278130) and its Form F-3 (File No. 333-259826).

Under which SEC form does Cellebrite DI Ltd. file annual reports?

Cellebrite DI Ltd. indicates that it files its annual reports under cover of Form 20-F as a foreign private issuer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the month of September 2025

Commission File Number 001-40772

Cellebrite DI Ltd.

(Translation of registrant’s name into English)

94 Shlomo Shmelzer Road

Petah Tikva 4970602, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒        Form 40-F ☐

EXPLANATORY NOTE

Cellebrite DI Ltd. (the “Company” or the “Registrant”) hereby announces that the shareholders of the Company approved all of the proposals brought before the annual general meeting of shareholders held on September 19, 2025 (the “Meeting”), by the respective requisite majority in accordance with the Israeli Companies Law, 5759-1999, and the Company’s articles of association, as described in the Proxy Statement which was attached as Exhibit 99.1 to the Company’s Report of Foreign Private Issuer on Form 6-K, furnished to the Securities and Exchange Commission (the “SEC”) on August 15, 2025, and sent in connection with the Meeting.

188,039,771 ordinary shares, representing approximately 76.82% of the issued and outstanding ordinary shares as of the record date, were present or represented by proxy at the Meeting.

This Report on Form 6-K is incorporated by reference into the Registrant’s registration statements on Form S-8 (File Nos. 333-260878 and 333-278130) filed with the SEC on November 8, 2021 and March 21, 2024, respectively, and Form F-3 (File No. 333-259826) filed with the SEC on September 13, 2022. 

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Cellebrite DI Ltd.
September 22, 2025	By:	/s/ Ayala Berler Shapira
		Ayala Berler Shapira
		General Counsel

2